Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T

摘要: Background Early identification of prognostic superior characteristics in glioma patients such as isocitrate dehydrogenase (IDH) mutation and O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status is great clinical importance. The study purpose was to investigate the non-invasive predictability IDH status, MGMT methylation, differentiation low-grade versus high-grade (LGG vs HGG) newly diagnosed employing relaxation-compensated multipool chemical exchange saturation transfer (CEST) MRI at 7.0 Tesla. Methods Thirty-one with were included this prospective study. CEST performed a 7T whole-body scanner. Nuclear Overhauser effect (NOE) isolated amide proton (APT; downfield NOE-suppressed APT = dns-APT) signals (mean value 90th signal percentile) quantitatively investigated whole tumor area regard mutation, LGG HGG. Statistics using receiver operating characteristic (ROC) under curve (AUC) analysis. Results compared advanced methods (apparent diffusion coefficient relative cerebral blood volume ROC/AUC analysis) obtained 3T. dns-APT yielded highest AUCs prediction (dns-APTmean 91.84%, P 0.05). Conclusions Relaxation-compensated MRI, particularly imaging, enabled HGG should therefore be considered MR biomarker diagnostic workup.